Literature DB >> 11309258

Existence of different alpha(1)-adrenoceptor subtypes in junctional and extrajunctional neurovascular regions in canine splenic arteries.

X P Yang1, S Chiba.   

Abstract

The present study attempted to characterize the alpha(1)-adrenoceptor subtypes mediating vasoconstrictor responses to administered and nerve stimulation-evoked noradrenaline (NA) release in the isolated and perfused canine splenic artery. A previous study demonstrated that periarterial electrical nerve stimulation (30 s trains of pulses at a frequency of 1, 4 or 10 Hz) induced a double peaked vasoconstriction consisting of an initial transient, predominantly P2X-purinoceptor-mediated constriction followed by a prolonged, mainly alpha(1)-adrenoceptor-mediated response in the canine splenic artery. The effects of alpha(1)-adrenoceptor subtype antagonists on neuronally-mediated second peaked vasoconstrictions were analysed. BMY 7378 (10 - 100 nM), a selective alpha(1D)-adrenoceptor antagonist produced a dose-dependent inhibition of the second peak responses at all frequencies used. BMY 7378 (100 nM) reduced these responses by approximately 30%. Exposure of tissues to chloroethylclonidine (CEC, 60 microM), a selective alpha(1B)-adrenoceptor antagonist attenuated the second peak response by approximately 60%, even in the presence of BMY 7378 (100 nM). On the other hand, WB 4101 (100 nM), a selective alpha(1A)-adrenoceptor antagonist potentiated nerve-stimulation-evoked double peaked vasoconstrictions, especially at low frequencies (1 and 4 Hz). Vasoconstrictor responses to administered NA were dose-dependently antagonized by WB 4101 (10 - 100 nM), but were not significantly affected by either BMY 7378 (10 - 100 nM) or by CEC (60 microM). The present results indicate that NA released from sympathetic nerves may junctionally exert its vasoconstrictor effect via activation of postjunctional alpha(1B)- and in part alpha(1D)-adrenoceptors, whereas exogenous NA extrajunctionally activates alpha(1A)-adrenoceptors to produce its vascular action in canine splenic arteries.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309258      PMCID: PMC1572737          DOI: 10.1038/sj.bjp.0704020

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Investigation of the subtypes of alpha1-adrenoceptor mediating contractions of rat vas deferens.

Authors:  V Honner; J R Docherty
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Effects of a selective neuropeptide Y Y(1) receptor antagonist BIBP 3226 on double peaked vasoconstrictor responses to periarterial nerve stimulation in canine splenic arteries.

Authors:  X P Yang; S Chiba
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

3.  Alpha 1-adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle.

Authors:  C Han; P W Abel; K P Minneman
Journal:  Nature       Date:  1987 Sep 24-30       Impact factor: 49.962

4.  BMY 7378, a buspirone analog with high affinity, selectivity and low intrinsic activity at the 5-HT1A receptor in rat and guinea pig hippocampal membranes.

Authors:  F D Yocca; D K Hyslop; D W Smith; S Maayani
Journal:  Eur J Pharmacol       Date:  1987-06-04       Impact factor: 4.432

5.  Periarterial electrical nerve stimulation-induced adrenergic vasoconstriction inhibited by adrenergic alpha1B-receptor blockade but not by alpha1A-blockade.

Authors:  X P Yang; S Chiba
Journal:  Jpn J Pharmacol       Date:  2000-11

6.  Dissociation of potentiation of Leu31 Pro34 neuropeptide Y on adrenergic and purinergic transmission in isolated canine splenic artery.

Authors:  X P Yang; S Chiba
Journal:  Jpn J Pharmacol       Date:  2000-07

7.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

8.  Adrenergic-purinergic interactions on vasoconstrictor responses to periarterial electric nerve stimulation in canine splenic arteries.

Authors:  X P Yang; S Chiba
Journal:  J Auton Pharmacol       Date:  1999-06

9.  Potentiating effect of methysergide on norepinephrine-induced constriction of the isolated internal carotid artery of the dog.

Authors:  T Tsuji; S Chiba
Journal:  Jpn J Pharmacol       Date:  1984-01

10.  A new method for measuring vascular responsiveness of relatively larger arteries of dogs.

Authors:  K Hongo; S Chiba
Journal:  J Pharmacol Methods       Date:  1983-02
View more
  5 in total

1.  Distribution of alpha-1 adrenoceptor subtypes in RNA and protein in rabbit eyes.

Authors:  Fumiko Suzuki; Takanobu Taniguchi; Seigo Nakamura; Yoshio Akagi; Chikara Kubota; Makoto Satoh; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Probenecid Inhibits α-Adrenergic Receptor-Mediated Vasoconstriction in the Human Leg Vasculature.

Authors:  Michael Nyberg; Peter Piil; Oliver T Kiehn; Christian Maagaard; Tue S Jørgensen; Jon Egelund; Brant E Isakson; Morten S Nielsen; Lasse Gliemann; Ylva Hellsten
Journal:  Hypertension       Date:  2017-10-30       Impact factor: 10.190

3.  Removal of half the sympathetic innervation does not reduce vasoconstrictor responses in rat tail artery.

Authors:  Diana Tripovic; Elspeth M McLachlan; James A Brock
Journal:  J Physiol       Date:  2013-04-03       Impact factor: 5.182

4.  The alpha1A-adrenoceptor gene is required for the alpha1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate.

Authors:  Kt Gray; Jl Short; S Ventura
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

5.  Alpha1-adrenoceptor subtypes involved in vasoconstrictor responses to exogenous and neurally released noradrenaline in rat femoral resistance arteries.

Authors:  Joseph Zacharia; Chris Hillier; Allan MacDonald
Journal:  Br J Pharmacol       Date:  2004-02-23       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.